Synergistic antitumor effects of novel HDAC inhibitors and paclitaxel in vitro and in vivo
about
Novel Natural Product- and Privileged Scaffold-Based Tubulin Inhibitors Targeting the Colchicine Binding SiteA Novel Indication for Panobinostat as a Senolytic Drug in NSCLC and HNSCC.Targeting Histone Deacetylases in Diseases: Where Are We?Epigenetic therapy in lung cancer.Synergistic action by multi-targeting compounds produces a potent compound combination for human NSCLC both in vitro and in vivo.Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models.Histone deacetylase 6 in health and disease.Targeting Chromatin-Mediated Transcriptional Control of Gene Expression in Non-Small Cell Lung Cancer Therapy: Preclinical Rationale and Clinical Results.Do Multiwell Plate High Throughput Assays Measure Loss of Cell Viability Following Exposure to Genotoxic Agents?Multinucleated Giant Cancer Cells Produced in Response to Ionizing Radiation Retain Viability and Replicate Their Genome.Belinostat and vincristine demonstrate mutually synergistic cytotoxicity associated with mitotic arrest and inhibition of polyploidy in a preclinical model of aggressive diffuse large B cell lymphoma.Anti-tumor activity of the combination of bendamustine with vorinostat in diffuse large B-cell lymphoma cells.A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer.Epigenetic therapy approaches in non-small cell lung cancer: Update and perspectives.p53 acetylation enhances Taxol-induced apoptosis in human cancer cells.Treatment of oral cancer using magnetized paclitaxel.The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease
P2860
Q28067375-AE4203A6-E986-492F-AE7B-EA741B307B0EQ33689457-791C1AD3-30B4-4147-A522-EAB4A52708AEQ35821728-A6AE34F4-652D-41BE-B3AB-ED969B3E24DDQ36885903-D30DAA62-38B4-4274-9F5A-2E4DEAA2D440Q37680216-D38A2806-8B11-4EA3-996D-08DE1068902FQ37709358-E21CB488-4C6C-4251-B115-A246F6DB75E8Q38357741-E3E09C83-E3CA-4000-A43F-F6A8E10B75C4Q38582589-5A314ACB-5D6C-4B1E-B989-442C7D328E69Q38647105-FBA67BC0-BCCD-4651-A405-983CD65F3D56Q38716153-6C511A06-978C-4372-82C8-61CBF478A6FAQ38735639-5310B118-4BF7-4AA8-9530-49C8A248DCB4Q38862949-67D0F49A-1487-4BFB-AFDC-4D8A4834F7ADQ38987825-0635F2C5-7124-4F56-B29D-A27C3A29A6E7Q39009379-F7C7AD83-08EB-4C7B-AF7F-987CA0DA5E00Q39242999-D1465C61-475B-4A32-98AC-24C66B9E0310Q52592872-6FA5E315-127B-4050-8A99-7598331DEDC0Q58792448-16B59FBD-C106-457B-BCCE-7EB9053959CC
P2860
Synergistic antitumor effects of novel HDAC inhibitors and paclitaxel in vitro and in vivo
description
2011 nî lūn-bûn
@nan
2011 թուականին հրատարակուած գիտական յօդուած
@hyw
2011 թվականին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Synergistic antitumor effects ...... aclitaxel in vitro and in vivo
@ast
Synergistic antitumor effects ...... aclitaxel in vitro and in vivo
@en
Synergistic antitumor effects ...... aclitaxel in vitro and in vivo
@nl
type
label
Synergistic antitumor effects ...... aclitaxel in vitro and in vivo
@ast
Synergistic antitumor effects ...... aclitaxel in vitro and in vivo
@en
Synergistic antitumor effects ...... aclitaxel in vitro and in vivo
@nl
prefLabel
Synergistic antitumor effects ...... aclitaxel in vitro and in vivo
@ast
Synergistic antitumor effects ...... aclitaxel in vitro and in vivo
@en
Synergistic antitumor effects ...... aclitaxel in vitro and in vivo
@nl
P2093
P2860
P50
P1433
P1476
Synergistic antitumor effects ...... aclitaxel in vitro and in vivo
@en
P2093
Claudio Pisano
Franco Zunino
Raffaella Cincinelli
Raffaella Nannei
P2860
P304
P356
10.1371/JOURNAL.PONE.0029085
P407
P577
2011-01-01T00:00:00Z